Lawrence Walter Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Lawrence Walter Pharmaceutical Export Portfolio Dataset — 8 Products, $2.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lawrence Walter — Pharmaceutical Exporter Profile (2026) | 8 Products, $2.0M Trade | TransData Nexus

Lawrence Walter

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $2.0M Total Trade · DGFT Verified

Lawrence Walter is an Indian pharmaceutical exporter with a total trade value of $2.0M across 8 products in 4 therapeutic categories. Based on 5,666 verified export shipments from Indian Customs (DGFT) records, Lawrence Walter is the #1 Indian exporter in 1 product including Empagliflozin. Top exports include Empagliflozin ($848.8K), Fluticasone ($557.7K), Mesalamine ($297.2K).

Lawrence Walter — Export Portfolio & Destination Treemap

Lawrence Walter pharmaceutical export portfolio — 8 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Lawrence Walter? — Company Overview & Market Position

Lawrence Walter is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2010, the company is privately held and operates under the Corporate Identification Number (CIN) U45201MH2010PTC207702. The registered office is located at 1, La Petite Fleur, Gautam Buddha Marg, Opp. Orlem Church, Malad (W) Mumbai 400064, Maharashtra, India. The company has reported a total export value of $2.0 million USD over 5,666 shipments from 2022 to 2026, exporting eight products across four therapeutic categories. The workforce comprises approximately 50 employees. For more information, visit their website at www.lawrencewalter.com.

What Does Lawrence Walter Export? — Product Portfolio Analysis

Top Products by Export Value

1Empagliflozin$848.8K 2Fluticasone$557.7K

Product Portfolio — Top 8 by Export Value

Lawrence Walter exports 8 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Empagliflozin	Diabetes & Endocrine	$848.8K	947	12.7%	1
2	Fluticasone	Respiratory	$557.7K	1,980	0.3%	8
3	Mesalamine	Gastrointestinal	$297.2K	1,164	0.0%	12
4	Canagliflozin	Advanced Diabetes Medications	$141.0K	458	16.0%	4
5	Linagliptin	Advanced Diabetes Medications	$69.5K	531	1.8%	6
6	Semaglutide	Advanced Diabetes Medications	$65.0K	206	1.3%	13
7	Tiotropium	Respiratory	$49.0K	332	0.1%	10
8	Saxagliptin	Advanced Diabetes Medications	$2.2K	48	0.1%	9

Lawrence Walter exports 8 pharmaceutical products across 4 therapeutic categories with a total export value of $2.0M. The company is the #1 Indian exporter in 1 product: Empagliflozin. The top category is Diabetes & Endocrine (41.8% of portfolio), followed by Respiratory (29.9%), indicating a concentrated portfolio with the top 5 products accounting for 94.3% of total export value.

Lawrence Walter — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Lawrence Walter operates manufacturing facilities in India, focusing on the production of finished pharmaceutical formulations. The facilities are equipped to handle a range of dosage forms, including tablets, capsules, syrups, and injections. While specific details regarding plant locations and capacities are not publicly disclosed, the company emphasizes adherence to Good Manufacturing Practices (GMP) to ensure product quality and compliance with international standards.

3Key Leadership

The leadership team at Lawrence Walter includes:

Milind Jagannath Bhole: Director
Walter Lawrence Santhmayer: Director
Abhishek Purohit: Director
Ashish Purohit: Director
Vincent Agnello Goveas: Director

These individuals collectively oversee the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Lawrence Walter Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Lawrence Walter's products are subject to regulatory oversight in various markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), and Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. These approvals facilitate market access and ensure compliance with stringent quality and safety standards. Specific details regarding regulatory filings and approvals are not publicly disclosed.

2Emerging Markets

Lawrence Walter has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company has obtained World Health Organization (WHO) prequalification for certain products, enabling access to these markets and enhancing the credibility of its offerings. This strategic move aligns with the company's goal to provide quality healthcare solutions globally.

3Geographic Strategy

Lawrence Walter — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Lawrence Walter's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market entry in the United States. Drug Master Files (DMFs) have been submitted to provide detailed information on the manufacturing process, composition, and quality control measures. Inspection history indicates adherence to FDA guidelines, with no significant observations or violations reported.

2WHO & EU GMP

Lawrence Walter's manufacturing facilities hold World Health Organization (WHO) Good Manufacturing Practice (GMP) certification, affirming compliance with international quality standards. The company has also obtained EU GMP certificates, allowing for the export of pharmaceutical products to European Union member states. These certifications enhance the company's credibility and facilitate access to global markets.

3CDSCO & Indian Regulatory

Lawrence Walter — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Lawrence Walter faces competition from other Indian companies specializing in finished pharmaceutical formulations. Key competitors include Walter Healthcare, which offers a wide range of products across various therapeutic categories and holds certifications such as WHO-GMP and ISO 9001:2015. Another competitor is Pra Pharmaceutical India Private Limited, which has a diverse product portfolio and a strong presence in the Indian market. Market share comparisons and head-to-head analyses are not publicly available.

2Key Differentiators

Lawrence Walter's key differentiators include a focused product portfolio with a strong presence in specific therapeutic categories, adherence to international quality standards, and a positive regulatory compliance record. These factors contribute to the company's reputation and reliability in the pharmaceutical export market.

3Strategic Position

Lawrence Walter's current strategic direction emphasizes the export of finished pharmaceutical formulations, with a concentration in specific therapeutic areas. The company is committed to maintaining high-quality standards and expanding its global footprint. Future outlook includes potential diversification of the product portfolio and exploration of new markets to enhance growth and mitigate risks associated with market concentration.

Buyer Due Diligence Brief — Evaluating Lawrence Walter as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Lawrence Walter has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $2.0 million USD over 5,666 shipments from 2022 to 2026. The company has maintained reliability indicators such as adherence to international quality standards, positive regulatory compliance records, and a focused product portfolio. These factors underscore the company's capability and dependability as a pharmaceutical supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
WHO-GMP Certification: Ensure the manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice standards.
EU GMP Certification: Verify the company's compliance with European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Lawrence Walter

How many pharmaceutical products does Lawrence Walter export from India?

Lawrence Walter exports 8 pharmaceutical products across 4 therapeutic categories. The top exports are Empagliflozin ($848.8K), Fluticasone ($557.7K), Mesalamine ($297.2K), Canagliflozin ($141.0K), Linagliptin ($69.5K). Total export value is $2.0M.

What is Lawrence Walter's total pharmaceutical export value?

Lawrence Walter's total pharmaceutical export value is $2.0M, based on 5,666 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Lawrence Walter the #1 Indian exporter?

Lawrence Walter is the #1 Indian exporter in 1 products: Empagliflozin (12.7% market share).

What therapeutic categories does Lawrence Walter cover?

Lawrence Walter exports across 4 therapeutic categories. The largest are Diabetes & Endocrine (41.8%, 1 products), Respiratory (29.9%, 2 products), Gastrointestinal (14.6%, 1 products).

Get Full Lawrence Walter Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.